Tirzepatide for adults living with obesity
Review (9 RCTs, n=7111) found tirzepatide likely results in weight loss at medium‐term follow‐up, and be sustained in longer‐term follow‐up, but long‐term impact on other patient‐important outcomes may be limited or uncertain.
Source:
Cochrane Database of Systematic Reviews
Further information:
Cochrane reviews of semaglutide and liraglutide for adults living with obesity have also been published.